Developer docs
API playgroundTry for free, no card

Search company profiles

CANbridge Pharmaceuticals

Full company profile

uuid0000h7v

Namestring
CANbridge Pharmaceuticals
Legal namestring
CANbridge Life Sciences Ltd.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

CANbridge Pharmaceuticals is a global biopharmaceutical company headquartered in Beijing, China, and listed on the Hong Kong Stock Exchange (HKEX:1228), focused on developing and commercializing therapeutics for rare diseases and rare oncology conditions. Founded in 2012 by Dr. James Xue, a former Genzyme China general manager, the company operates three approved drugs: Hunterase (idursulfase beta) for MPS II, Livmarli (maralixibat) for ALGS and PFIC cholestatic pruritus, and Gaurunning (velaglucerase-beta) for Gaucher disease, with the latter representing the first domestically developed enzyme replacement therapy in China. The pipeline includes seven or more assets spanning monoclonal antibodies (CAN106 for PNH), additional enzyme replacement therapies, and gene therapies (CAN201, CAN202, CAN203, CAN204) targeting Fabry disease, Pompe disease, SMA, and Duchenne muscular dystrophy using proprietary AAV delivery platforms including sL65 capsid technology and StitchR RNA Assembly Technology licensed from LogicBio and Scriptr Global respectively.

The company's business model combines in-licensing of global rare disease assets for the Greater China market with proprietary R&D and gene therapy platform development. Revenue is generated through direct commercialization in mainland China via a sales-led motion, supplemented by regional distribution partners in Hong Kong and Taiwan, plus licensing and royalty income from outbound partnerships (e.g., Mirum Pharma, GC Pharma). CANbridge operates offices across Beijing, Shanghai, Hong Kong, Taipei, Burlington (Massachusetts), and a manufacturing facility in Suzhou, supported by approximately 101-250 employees of whom 42% hold Ph.D. or M.D. degrees. Strategic shareholders include WuXi AppTec (corporate investment plus board representation since June 2025) and Baheal Pharmaceutical Group (strategic partnership and investment since August 2025), while the company maintains research collaborations with UMass Chan Medical School and the University of Washington School of Medicine.

The competitive positioning leverages first-mover advantage in China's rare disease therapeutics market, exclusive Greater China distribution rights from multiple global partners, and priority review regulatory pathways granted by NMPA. The company has secured orphan drug designations and established an integrated manufacturing capability via the MAH system in China. Key revenue drivers include NRDL inclusion for three rare disease drugs in 2025 and Commercial Health Insurance Innovative Drug List placement for Gaurunning, though the company has historically operated at a loss with improving EBITDA trajectory and a recent net income inflection.

Short descriptiontext

CANbridge Pharmaceuticals is a Beijing-based, HKEX-listed biopharmaceutical company developing and commercializing rare disease therapeutics for the Greater China market, with three approved drugs (Hunterase, Livmarli, Gaurunning) and a pipeline spanning gene therapies and biologics targeting lysosomal storage disorders, cholestatic liver diseases, and neuromuscular conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, enzyme replacement therapy, gene therapy development, orphan drug commercialization, biopharmaceutical products
Industry1 code
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from commercialization of approved rare disease drugs including Hunterase, Livmarli, and Gaurunning in Greater China markets

canbridgepharma.com
2Licensing and Royalty Revenue
TypeLicensing Royalties
Description

Income from licensing agreements with global partners for development and commercialization rights

canbridgepharma.com
3Strategic Partnerships
TypeProfessional Services
Description

Collaborations with WuXi Biologics, Mirum Pharma, GC Pharma providing development milestones and commercialization support

canbridgepharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CANbridge Pharmaceuticals develops, manufactures, and commercializes therapeutics for rare diseases and rare oncology, anchored by three approved drugs — Hunterase® (MPS II), Livmarli® (ALGS/PFIC), and Gaurunning® (Gaucher disease) — sold in Greater China through a direct sales force and regional distributors. Its pipeline extends these capabilities with a long-acting anti-C5 monoclonal antibody (CAN106) for complement-mediated diseases and a gene therapy portfolio (CAN201, CAN202, CAN204) built on AAV/sL65 delivery and StitchR RNA Assembly Technology, supplemented by in-licensed products and global licensing partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CAN103 pivotal trial met primary endpoint with statistically significant mean percentage reduction in spleen volume at 9 months (P<0.0001 for 60 U/kg, P<0.001 for 30 U/kg)
+2 more records
Product overview1 text field

CANbridge Pharmaceuticals is a global biopharmaceutical company with a foundation in China focused on rare diseases and rare oncology. The company operates a differentiated drug portfolio comprising 3 approved drugs (Gaurunning®, Livmarli®, and Hunterase®) and a pipeline of 7+ assets in various stages of development. The approved products include enzyme replacement therapies (ERTs) for lysosomal storage disorders like Gaucher disease and MPS II, and an IBAT inhibitor for rare cholestatic liver diseases. The pipeline includes biologics (monoclonal antibodies like CAN106), small molecules, and gene therapies targeting conditions such as complement-mediated disorders, metabolic diseases, and neuromuscular diseases. The company is also developing next-generation gene therapies for rare genetic diseases including Pompe disease, Fabry disease, and Duchenne muscular dystrophy through its Next-Generation Innovation and Process Development Facility.

Product and service7 records
1Hunterase® (Idursulfase beta / CAN101)
CategoryEnzyme Replacement Therapy
Description

Recombinant human iduronate-2-sulfatase enzyme replacement therapy (ERT) for long-term treatment of patients with mucopolysaccharidosis type II (MPS II / Hunter syndrome); marketed in mainland China, Hong Kong, and Taiwan.

2Livmarli® (Maralixibat / CAN108)
CategoryOral Rare-Disease Therapeutic
Description

Oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT) for treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC); marketed in mainland China, Hong Kong, and Taiwan.

3Gaurunning® (Velaglucerase Beta for Injection / CAN103)
CategoryEnzyme Replacement Therapy
Description

Recombinant human glucocerebrosidase enzyme replacement therapy for long-term treatment of adult and pediatric patients (12 years and older) with Type 1 and Type 3 Gaucher disease; the first domestically developed ERT for Gaucher disease in China.

4CAN106 (Omoprubart)
CategoryMonoclonal Antibody Biologic
Description

Novel, long-acting monoclonal antibody that specifically binds and neutralizes complement C5, being developed for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases including myasthenia gravis; partnered with Privus, which holds rights outside Greater China.

5CAN201 (Fabry disease gene therapy)
CategoryGene Therapy
Description

AAV-based gene therapy using the sL65 capsid for treatment of Fabry disease (Anderson-Fabry disease), a lysosomal storage disease caused by deficiency of the alpha-galactosidase A enzyme; leverages gene delivery platform licensed from LogicBio Therapeutics.

6CAN202 (Pompe disease gene therapy)
CategoryGene Therapy
Description

AAV-based gene therapy using the sL65 capsid for treatment of Pompe disease (Glycogen Storage Disease Type II), an autosomal recessive metabolic disease causing muscle and nerve cell damage due to glycogen accumulation in lysosomes.

7CAN204 (DMD/BMD gene therapy program)
CategoryGene Therapy
Description

Dual AAV vector gene therapy using the StitchR RNA Assembly Technology for treatment of dystrophinopathies including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy; co-developed with University of Washington School of Medicine.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Baheal (百洋医药)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

Strategic partnership and investment from Baheal to strengthen commercialization of rare disease products. Baheal provides commercial capabilities and strategic investment.

canbridgepharma.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-01-01
Description

Partnership for CAN106 (omoprubart) complement C5 antibody with Privus holding rights outside Greater China while CANbridge has Greater China rights.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Research agreement for Duchenne muscular dystrophy gene therapy development.

4Scriptr Global
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-10-01
Description

Licensed StitchR RNA Assembly Technology globally for development of gene therapies targeting dystrophinopathies including DMD, BMD, and X-linked dilated cardiomyopathy. Published research in Science journal.

canbridgepharma.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-04-01
Description

Licensed gene delivery and editing technology platforms including sL65 capsid for development of gene therapies targeting Fabry disease and Pompe disease. Acquired global exclusive rights for the sL65 AAV capsid technology.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-04-01
Description

Exclusive licensing agreement to develop and commercialize maralixibat (Livmarli/CAN108) in Greater China for rare liver diseases including ALGS and PFIC. Mirum holds US/EU rights while CANbridge has Greater China rights.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-01
Description

Research collaboration for rare disease gene therapies. Partnership expanded with second agreement in September 2020. Includes development of SMA gene therapy (CAN203) and collaboration on AAV delivery platforms.

8GC Pharma
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-01-01
Description

Licensed Hunterase (idursulfase beta) for MPS II treatment in Greater China. GC Pharma originally developed Hunterase and maintains manufacturing capabilities while CANbridge commercializes in Greater China.

canbridgepharma.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-10-01
Description

Strategic partnership for rare disease therapeutics development. WuXi Biologics collaborated with CANbridge on CAN103 (velaglucerase-beta) development - the first enzyme replacement therapy developed in China for Gaucher disease. WuXi Biologics provides manufacturing capabilities and technology transfer for the MAH system.

10Apogenix
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2015-07-01
Description

Licensed CAN008 (asunercept) for treatment of glioblastoma multiforme in Greater China. CANbridge holds exclusive rights for any indication development in the region.

canbridgepharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-founded, US/HK-listed biopharma licensing global innovative therapies for Greater China commercialization. Highly comparable bridge model with approved products across oncology and rare diseases, similar HKEX listing profile, and analogous reliance on in-licensed assets.

TypeDirect peer
Description

Hong Kong-listed clinical-stage biopharma focused on licensing and developing innovative therapies for Asia-Pacific markets, including rare and infectious diseases. Directly comparable GTM (bridge model, HKEX listing) and overlapping rare disease focus.

TypeDirect peer
Description

US rare disease biopharma developing Livmarli (maralixibat) for ALGS/PFIC and other cholestatic diseases. Direct counterparty and licensor to CANbridge; comparable business model centered on a single rare disease franchise with global rights.

TypeDirect peer
Description

Korean biopharma that developed Hunterase (idursulfase beta) for MPS II. Originator and licensor of one of CANbridge's flagship products; similar rare disease focus with established ERT portfolio across Asia.

TypeBroad incumbent
Description

Global rare disease leader with multiple approved enzyme replacement and gene therapies (Vimizim, Naglazyme, Aldurazyme, Roctavian). Overlaps with CANbridge's Gaucher/MPS/gene therapy areas and represents the dominant global competitor in lysosomal storage disorders.

TypeBroad incumbent
Description

US rare and ultra-rare disease biopharma with approved ERTs (Crysvita, Mepsevii, Dojolvi) and a gene therapy pipeline. Directly comparable in commercial-stage rare disease biologics and gene therapy modality.

TypeBroad incumbent
Description

Global rare disease franchise of Sanofi, the dominant player in lysosomal storage disorders (Cerezyme, Fabrazyme, Aldurazyme, Elaprase, Cerezyme). CANbridge's leadership is largely ex-Genzyme and the franchise's product overlap (Gaucher, MPS) makes it the benchmark competitor in China.

8I-Mab Biopharma
TypeRegional player
Description

China-focused clinical-stage biopharma with oncology and immunology focus; comparable HKEX/Nasdaq-listed structure, China innovation pipeline, and overlap in board-level rare disease regulatory talent (Rebecca Zhang, now CANbridge's Chief Regulatory Advisor, was previously Head of RA at I-Mab).

TypeBroad incumbent
Description

China-founded biopharma with HKEX listing and integrated R&D-manufacturing-commercial capabilities. Comparable scale, public-market profile, and Suzhou-based manufacturing footprint (CANbridge's Will Wang previously served at Innovent).

TypeEmerging player
Description

US clinical-stage gene therapy company developing AAV-based therapies for CNS diseases, co-founded by CANbridge SAB member Guangping Gao. Comparable gene therapy platform technology and shared scientific heritage in AAV delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CANbridge Pharmaceuticals

Rare Disease Biopharmaceuticalscanbridgepharma.com

CANbridge Pharmaceuticals is a Beijing-based, HKEX-listed biopharmaceutical company developing and commercializing rare disease therapeutics for the Greater China market, with three approved drugs (Hunterase, Livmarli, Gaurunning) and a pipeline spanning gene therapies and biologics targeting lysosomal storage disorders, cholestatic liver diseases, and neuromuscular conditions.

What CANbridge Pharmaceuticals does

CANbridge Pharmaceuticals is a global biopharmaceutical company headquartered in Beijing, China, and listed on the Hong Kong Stock Exchange (HKEX:1228), focused on developing and commercializing therapeutics for rare diseases and rare oncology conditions. Founded in 2012 by Dr. James Xue, a former Genzyme China general manager, the company operates three approved drugs: Hunterase (idursulfase beta) for MPS II, Livmarli (maralixibat) for ALGS and PFIC cholestatic pruritus, and Gaurunning (velaglucerase-beta) for Gaucher disease, with the latter representing the first domestically developed enzyme replacement therapy in China. The pipeline includes seven or more assets spanning monoclonal antibodies (CAN106 for PNH), additional enzyme replacement therapies, and gene therapies (CAN201, CAN202, CAN203, CAN204) targeting Fabry disease, Pompe disease, SMA, and Duchenne muscular dystrophy using proprietary AAV delivery platforms including sL65 capsid technology and StitchR RNA Assembly Technology licensed from LogicBio and Scriptr Global respectively.

The company's business model combines in-licensing of global rare disease assets for the Greater China market with proprietary R&D and gene therapy platform development. Revenue is generated through direct commercialization in mainland China via a sales-led motion, supplemented by regional distribution partners in Hong Kong and Taiwan, plus licensing and royalty income from outbound partnerships (e.g., Mirum Pharma, GC Pharma). CANbridge operates offices across Beijing, Shanghai, Hong Kong, Taipei, Burlington (Massachusetts), and a manufacturing facility in Suzhou, supported by approximately 101-250 employees of whom 42% hold Ph.D. or M.D. degrees. Strategic shareholders include WuXi AppTec (corporate investment plus board representation since June 2025) and Baheal Pharmaceutical Group (strategic partnership and investment since August 2025), while the company maintains research collaborations with UMass Chan Medical School and the University of Washington School of Medicine.

The competitive positioning leverages first-mover advantage in China's rare disease therapeutics market, exclusive Greater China distribution rights from multiple global partners, and priority review regulatory pathways granted by NMPA. The company has secured orphan drug designations and established an integrated manufacturing capability via the MAH system in China. Key revenue drivers include NRDL inclusion for three rare disease drugs in 2025 and Commercial Health Insurance Innovative Drug List placement for Gaurunning, though the company has historically operated at a loss with improving EBITDA trajectory and a recent net income inflection.

CANbridge Pharmaceuticals firmographics

Firmographics
Name
CANbridge Pharmaceuticals
Legal name
CANbridge Life Sciences Ltd.
Website
https://canbridgepharma.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
CANbridge Pharmaceuticals is a Beijing-based, HKEX-listed biopharmaceutical company developing and commercializing rare disease therapeutics for the Greater China market, with three approved drugs (Hunterase, Livmarli, Gaurunning) and a pipeline spanning gene therapies and biologics targeting lysosomal storage disorders, cholestatic liver diseases, and neuromuscular conditions.
Ownership category
akta.pro rank

CANbridge Pharmaceuticals industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Rare disease therapeutics
  • Enzyme replacement therapy
  • Gene therapy development
  • Orphan drug commercialization
  • Biopharmaceutical products

Where CANbridge Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices6 records

Markets served

CANbridge Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Pharmaceutical Product Sales: Revenue from commercialization of approved rare disease drugs including Hunterase, Livmarli, and Gaurunning in Greater China markets
  2. Licensing and Royalty Revenue: Income from licensing agreements with global partners for development and commercialization rights
  3. Strategic Partnerships: Collaborations with WuXi Biologics, Mirum Pharma, GC Pharma providing development milestones and commercialization support

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

CANbridge Pharmaceuticals product offering

Product offering

Core offering

CANbridge Pharmaceuticals develops, manufactures, and commercializes therapeutics for rare diseases and rare oncology, anchored by three approved drugs — Hunterase® (MPS II), Livmarli® (ALGS/PFIC), and Gaurunning® (Gaucher disease) — sold in Greater China through a direct sales force and regional distributors. Its pipeline extends these capabilities with a long-acting anti-C5 monoclonal antibody (CAN106) for complement-mediated diseases and a gene therapy portfolio (CAN201, CAN202, CAN204) built on AAV/sL65 delivery and StitchR RNA Assembly Technology, supplemented by in-licensed products and global licensing partnerships.

Product overview

CANbridge Pharmaceuticals is a global biopharmaceutical company with a foundation in China focused on rare diseases and rare oncology. The company operates a differentiated drug portfolio comprising 3 approved drugs (Gaurunning®, Livmarli®, and Hunterase®) and a pipeline of 7+ assets in various stages of development. The approved products include enzyme replacement therapies (ERTs) for lysosomal storage disorders like Gaucher disease and MPS II, and an IBAT inhibitor for rare cholestatic liver diseases. The pipeline includes biologics (monoclonal antibodies like CAN106), small molecules, and gene therapies targeting conditions such as complement-mediated disorders, metabolic diseases, and neuromuscular diseases. The company is also developing next-generation gene therapies for rare genetic diseases including Pompe disease, Fabry disease, and Duchenne muscular dystrophy through its Next-Generation Innovation and Process Development Facility.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hunterase® (Idursulfase beta / CAN101) Recombinant human iduronate-2-sulfatase enzyme replacement therapy (ERT) for long-term treatment of patients with mucopolysaccharidosis type II (MPS II / Hunter syndrome); marketed in mainland China, Hong Kong, and Taiwan.
  • Livmarli® (Maralixibat / CAN108) Oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT) for treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC); marketed in mainland China, Hong Kong, and Taiwan.
  • Gaurunning® (Velaglucerase Beta for Injection / CAN103) Recombinant human glucocerebrosidase enzyme replacement therapy for long-term treatment of adult and pediatric patients (12 years and older) with Type 1 and Type 3 Gaucher disease; the first domestically developed ERT for Gaucher disease in China.
  • CAN106 (Omoprubart) Novel, long-acting monoclonal antibody that specifically binds and neutralizes complement C5, being developed for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases including myasthenia gravis; partnered with Privus, which holds rights outside Greater China.
  • CAN201 (Fabry disease gene therapy) AAV-based gene therapy using the sL65 capsid for treatment of Fabry disease (Anderson-Fabry disease), a lysosomal storage disease caused by deficiency of the alpha-galactosidase A enzyme; leverages gene delivery platform licensed from LogicBio Therapeutics.
  • CAN202 (Pompe disease gene therapy) AAV-based gene therapy using the sL65 capsid for treatment of Pompe disease (Glycogen Storage Disease Type II), an autosomal recessive metabolic disease causing muscle and nerve cell damage due to glycogen accumulation in lysosomes.
  • CAN204 (DMD/BMD gene therapy program) Dual AAV vector gene therapy using the StitchR RNA Assembly Technology for treatment of dystrophinopathies including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy; co-developed with University of Washington School of Medicine.

Quantifiable outcome

  • CAN103 pivotal trial met primary endpoint with statistically significant mean percentage reduction in spleen volume at 9 months (P<0.0001 for 60 U/kg, P<0.001 for 30 U/kg)
  • +2 more outcomes

Companies that use CANbridge Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

CANbridge Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CANbridge Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Baheal (百洋医药)coreStrategic or Co-development Partner · 1 August 2025Strategic partnership and investment from Baheal to strengthen commercialization of rare disease products. Baheal provides commercial capabilities and strategic investment.
  • PrivusminorOEM/ Whitelabel/ Licensing Partner · 1 January 2023Partnership for CAN106 (omoprubart) complement C5 antibody with Privus holding rights outside Greater China while CANbridge has Greater China rights.
  • University of Washington School of MedicineminorStrategic or Co-development Partner · 1 November 2021Research agreement for Duchenne muscular dystrophy gene therapy development.
  • Scriptr GlobalcoreTechnology or Integration · 1 October 2021Licensed StitchR RNA Assembly Technology globally for development of gene therapies targeting dystrophinopathies including DMD, BMD, and X-linked dilated cardiomyopathy. Published research in Science journal.
  • LogicBio TherapeuticscoreTechnology or Integration · 1 April 2021Licensed gene delivery and editing technology platforms including sL65 capsid for development of gene therapies targeting Fabry disease and Pompe disease. Acquired global exclusive rights for the sL65 AAV capsid technology.
  • Mirum PharmacoreOEM/ Whitelabel/ Licensing Partner · 1 April 2021Exclusive licensing agreement to develop and commercialize maralixibat (Livmarli/CAN108) in Greater China for rare liver diseases including ALGS and PFIC. Mirum holds US/EU rights while CANbridge has Greater China rights.
  • UMass Chan Medical SchoolcoreStrategic or Co-development Partner · 1 June 2020Research collaboration for rare disease gene therapies. Partnership expanded with second agreement in September 2020. Includes development of SMA gene therapy (CAN203) and collaboration on AAV delivery platforms.
  • GC PharmacoreOEM/ Whitelabel/ Licensing Partner · 1 January 2019Licensed Hunterase (idursulfase beta) for MPS II treatment in Greater China. GC Pharma originally developed Hunterase and maintains manufacturing capabilities while CANbridge commercializes in Greater China.
  • WuXi Biologics (药明生物)coreTechnology or Integration · 1 October 2018Strategic partnership for rare disease therapeutics development. WuXi Biologics collaborated with CANbridge on CAN103 (velaglucerase-beta) development - the first enzyme replacement therapy developed in China for Gaucher disease. WuXi Biologics provides manufacturing capabilities and technology transfer for the MAH system.
  • ApogenixminorOEM/ Whitelabel/ Licensing Partner · 1 July 2015Licensed CAN008 (asunercept) for treatment of glioblastoma multiforme in Greater China. CANbridge holds exclusive rights for any indication development in the region.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

CANbridge Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Zai Lab: China-founded, US/HK-listed biopharma licensing global innovative therapies for Greater China commercialization. Highly comparable bridge model with approved products across oncology and rare diseases, similar HKEX listing profile, and analogous reliance on in-licensed assets.
  • Everest Medicines: Hong Kong-listed clinical-stage biopharma focused on licensing and developing innovative therapies for Asia-Pacific markets, including rare and infectious diseases. Directly comparable GTM (bridge model, HKEX listing) and overlapping rare disease focus.
  • Mirum Pharmaceuticals: US rare disease biopharma developing Livmarli (maralixibat) for ALGS/PFIC and other cholestatic diseases. Direct counterparty and licensor to CANbridge; comparable business model centered on a single rare disease franchise with global rights.
  • GC Pharma (Green Cross Corporation): Korean biopharma that developed Hunterase (idursulfase beta) for MPS II. Originator and licensor of one of CANbridge's flagship products; similar rare disease focus with established ERT portfolio across Asia.

Broad incumbents

  • BioMarin Pharmaceutical: Global rare disease leader with multiple approved enzyme replacement and gene therapies (Vimizim, Naglazyme, Aldurazyme, Roctavian). Overlaps with CANbridge's Gaucher/MPS/gene therapy areas and represents the dominant global competitor in lysosomal storage disorders.
  • Ultragenyx Pharmaceutical: US rare and ultra-rare disease biopharma with approved ERTs (Crysvita, Mepsevii, Dojolvi) and a gene therapy pipeline. Directly comparable in commercial-stage rare disease biologics and gene therapy modality.
  • Sanofi Genzyme: Global rare disease franchise of Sanofi, the dominant player in lysosomal storage disorders (Cerezyme, Fabrazyme, Aldurazyme, Elaprase, Cerezyme). CANbridge's leadership is largely ex-Genzyme and the franchise's product overlap (Gaucher, MPS) makes it the benchmark competitor in China.
  • Innovent Biologics: China-founded biopharma with HKEX listing and integrated R&D-manufacturing-commercial capabilities. Comparable scale, public-market profile, and Suzhou-based manufacturing footprint (CANbridge's Will Wang previously served at Innovent).

Regional players

  • I-Mab Biopharma: China-focused clinical-stage biopharma with oncology and immunology focus; comparable HKEX/Nasdaq-listed structure, China innovation pipeline, and overlap in board-level rare disease regulatory talent (Rebecca Zhang, now CANbridge's Chief Regulatory Advisor, was previously Head of RA at I-Mab).

Emerging players

  • Voyager Therapeutics: US clinical-stage gene therapy company developing AAV-based therapies for CNS diseases, co-founded by CANbridge SAB member Guangping Gao. Comparable gene therapy platform technology and shared scientific heritage in AAV delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

CANbridge Pharmaceuticals social profiles

Digital presence

CANbridge Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CANbridge Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles19 records

CANbridge Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CANbridge Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CANbridge Pharmaceuticals

What does CANbridge Pharmaceuticals do?

CANbridge Pharmaceuticals develops, manufactures, and commercializes therapeutics for rare diseases and rare oncology, anchored by three approved drugs — Hunterase® (MPS II), Livmarli® (ALGS/PFIC), and Gaurunning® (Gaucher disease) — sold in Greater China through a direct sales force and regional distributors. Its pipeline extends these capabilities with a long-acting anti-C5 monoclonal antibody (CAN106) for complement-mediated diseases and a gene therapy portfolio (CAN201, CAN202, CAN204) built on AAV/sL65 delivery and StitchR RNA Assembly Technology, supplemented by in-licensed products and global licensing partnerships.

Is CANbridge Pharmaceuticals a public or private company?

CANbridge Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was CANbridge Pharmaceuticals founded?

CANbridge Pharmaceuticals was founded in 2012. It employs 101 to 250 people.

Where is CANbridge Pharmaceuticals based?

CANbridge Pharmaceuticals is headquartered in Burlington, United States, in the North America region.

How does CANbridge Pharmaceuticals make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Royalty Revenue and strategic Partnerships.

Who are CANbridge Pharmaceuticals's main competitors?

Direct peers on record are Zai Lab, Everest Medicines, Mirum Pharmaceuticals and GC Pharma (Green Cross Corporation). Broad incumbents are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Sanofi Genzyme and Innovent Biologics. I-Mab Biopharma is listed as a regional player. Voyager Therapeutics is listed as an emerging player.

Does CANbridge Pharmaceuticals have an API?

No public API is recorded for CANbridge Pharmaceuticals.

What industry is CANbridge Pharmaceuticals in?

CANbridge Pharmaceuticals's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaChina's Push To Expand Access To Costly Therapies And A Partnership Deal Boost Rare Drugs Maker - But IsCANbridge Pharmaceuticals Inc., a Hong Kong-listed rare disease drug maker, saw its stock price surge 1,591% from late May to mid-August 2025, driven by regulatory approval for a Gaucher disease treatment, inclusion of three products in a preliminary commercial medical insurance catalogue, and a strategic partnership with Qingdao Baheal Medical Inc. that included a HK$100 million equity stake purchase giving Baheal Medical approximately 14.99% ownership. The partnership also helped ease CANbridge's acute cash flow crisis, as the company reported 2024 revenue of 85.10 million yuan, a net loss of 443 million yuan, and only 10.5 million yuan in available cash at year-end.YahooWuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPAWuXi Biologics and CANbridge Pharmaceuticals announced the China NMPA approval of velaglucerase-beta for injection (Gaurunning) for Gaucher disease in adolescents and adults. The product is China's first locally developed enzyme replacement therapy for the disease, with yield increased over 110 times and enzyme activity up 50%.PR NewswireCANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual CongressCANbridge Pharmaceuticals announced that preclinical data for CAN201, a gene therapy candidate for Fabry disease, will be presented at the ESGCT 30th Annual Congress in Brussels, Belgium from October 24-27, 2023. The preclinical studies in Fabry mice and humanized liver mouse models demonstrated dose-dependent increases in α-GAL enzyme levels with corresponding reductions in disease-causing Gb3 lipid levels, with no significant adverse effects observed. CANbridge holds an exclusive global license from LogicBio Therapeutics to develop, manufacture and commercialize gene therapy candidates for Fabry and Pompe diseases based on LogicBio's AAV sL65 technology.PR NewswireCANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products AdministrationCANbridge Pharmaceuticals announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application for CAN108 (LIVMARLI®) to treat cholestatic pruritus in patients two months and older with progressive familial intrahepatic cholestasis (PFIC), a rare genetic liver disorder. The application has been granted priority review and is based on data from the MARCH PFIC Phase 3 study, the largest randomized trial in PFIC with 93 patients, which showed statistically significant improvements in pruritus, serum bile acids, bilirubin, and growth. LIVMARLI is already approved for Alagille syndrome in China, and this approval would expand the label for the rare disease therapy in the Chinese market.PR NewswireCANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in ChinaCANbridge Pharmaceuticals announced full enrollment has been reached in the core part of its ongoing CAN103 Phase 2 trial for Gaucher disease Types I and III in treatment-naïve patients aged 12 and above in China. CAN103 is the first clinical-stage enzyme replacement therapy being developed for Gaucher disease in China and this trial is intended to serve as a potential registrational trial. With approximately 3,000 GD patients in China and most lacking access to approved ERT treatments due to reimbursement barriers, the therapy addresses a significant unmet medical need in the country.PR NewswireCANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)CANbridge Pharmaceuticals received marketing approval from Taiwan's Food and Drug Administration for LIVMARLI (CAN108) to treat cholestatic pruritus in patients with Alagille syndrome aged one year or older, making it the first and only approved treatment for this condition in Taiwan. The approval was based on data from Mirum Pharmaceuticals' pivotal ICONIC study and RISE infant safety study, with CANbridge holding an exclusive license for development and commercialization of LIVMARLI in Greater China. The approval follows recent authorizations in mainland China and Hong Kong within six months, expanding patient access across the region for this rare genetic disorder that can lead to end-stage liver disease.PR NewswireCANbridge to Participate in Two Investor Conferences in SeptemberCANbridge Pharmaceuticals Inc. announced that its founder, chairman, and CEO James Xue along with CFO Glenn Hassan will participate in two investor conferences in New York this September. The company highlighted its portfolio of four approved drugs and a pipeline of ten assets targeting rare diseases and oncology during the presentations at the Morgan Stanley and H.C. Wainwright conferences.PR NewswireCANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023CANbridge Pharmaceuticals reported a 24.2% increase in revenue to RMB43.1 million for the first half of 2023, driven by sales growth of Hunterase and Livmarli, while reducing its net loss. The company received approval from China's National Medical Products Administration for Livmarli to treat cholestatic pruritus in Alagille syndrome patients and announced positive Phase 1b data for its CAN106 therapy in paroxysmal nocturnal hemoglobinuria. Looking ahead, CANbridge plans to launch Livmarli in China in Q1 2024 and initiate a Phase 2 trial for CAN106 later this year.BioSpaceCANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy ResearchCANbridge Pharmaceuticals appointed Jason West, Ph.D., as Vice President, Head of Gene Therapy Research, effective immediately. He previously led gene therapy programs at Fractyl Health and CRISPR Therapeutics. The appointment supports CANbridge's gene therapy programs in spinal muscular atrophy, Duchenne muscular dystrophy, and Fabry disease.